MAPK3 and neoplasm: Recent research has underscored the intricate nature of the mechanisms by which ERK1/2 is activated and the subsequent implications for tumor biology, illustrating both the oncogenic capabilities and the therapeutic hurdles linked to the modulation of this pathway.